3D Printed Drugs Market Segmentation:
Technology (Inkjet Printing, Zipdose Technology, Stereolithography)
The zipdose technology segment is expected to hold largest 3D printed drugs market share by 2034, owing to rise in the number of people suffering from dysphagia. It was observed that the prevalence of dysphagia in hospitalized patients ranges from 15% to 17%. Approximately 31% to 59% of nursing home residents suffer from dysphagia symptoms. In addition to being easy to use, this makes swallowing the drugs easier and proves to be effective for patients with dysphagia. Moreover, the growing demand for quickly dispersible drugs among geriatric and pediatric patients will boost the segment growth.
Our in-depth analysis of the global drugs market includes the following segments:
|
By Technology |
|
|
By Application |
|
|
By End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of 3D printed drugs is estimated at USD 118.84 million.
3D Printed Drugs Market size was valued at USD 105.24 million in 2024 and is set to exceed USD 433.22 million by 2034, registering over 15.2% CAGR during the forecast period i.e., between 2025-2034.
North America is poised to account for largest industry share by 2034.
The key market players include Extend Biosciences, Bioduro, Affinity Therapeutics, Osmotica Pharmaceuticals, Acrux, Thiomatrix, Ico Therapeutics Inc., Formac Pharmaceuticals, BiopharmX, Pacira Pharmaceuticals Inc.
